Jasper Therapeutics (JSPR) to Release Quarterly Earnings on Thursday

Jasper Therapeutics (NASDAQ:JSPR) is projected to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Jasper Therapeutics to post earnings of ($0.79) per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, February 27, 2026 at 12:30 PM ET.

Jasper Therapeutics Stock Performance

Shares of NASDAQ JSPR opened at $1.34 on Thursday. Jasper Therapeutics has a one year low of $1.11 and a one year high of $7.19. The firm has a fifty day moving average of $1.59 and a 200 day moving average of $2.08. The firm has a market cap of $37.49 million, a PE ratio of -0.23 and a beta of 3.08.

Wall Street Analysts Forecast Growth

JSPR has been the subject of a number of recent research reports. Rodman & Renshaw started coverage on shares of Jasper Therapeutics in a report on Tuesday, January 13th. They issued a “buy” rating and a $17.00 price objective for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Thursday, January 22nd. Seven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.88.

Institutional Investors Weigh In On Jasper Therapeutics

Several hedge funds have recently modified their holdings of JSPR. Goldman Sachs Group Inc. increased its holdings in Jasper Therapeutics by 6,394.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,746,492 shares of the company’s stock valued at $3,196,000 after acquiring an additional 1,719,602 shares in the last quarter. Acorn Capital Advisors LLC acquired a new stake in shares of Jasper Therapeutics during the 3rd quarter worth $3,291,000. Velan Capital Investment Management LP lifted its stake in shares of Jasper Therapeutics by 86.1% in the 3rd quarter. Velan Capital Investment Management LP now owns 2,668,395 shares of the company’s stock valued at $6,206,000 after purchasing an additional 1,234,567 shares in the last quarter. Woodline Partners LP purchased a new position in shares of Jasper Therapeutics in the 3rd quarter valued at $2,475,000. Finally, Millennium Management LLC grew its stake in shares of Jasper Therapeutics by 194.2% in the fourth quarter. Millennium Management LLC now owns 1,073,783 shares of the company’s stock valued at $1,965,000 after buying an additional 708,844 shares in the last quarter. 79.85% of the stock is owned by institutional investors and hedge funds.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.